Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Inclusion Criteria: * Diagnosis of CKD * eGFR \< 60 mL/min/1.73m\^2 during the screening period * Not receiving dialysis for 8 weeks prior to the screening period, and not expected to start dialysis during the treatment period * Correction group: Not being treated with ESAs for the recent 8 weeks prior to the screening period * Conversion group: Being treated with ESAs for the recent 8 weeks prior to the screening period * Mean of the two screening Hb levels closest in time to the baseline visit. Correction group: ≥8.0 g/dL and \< 11.0 g/dL Conversion group: ≥9.0 g/dL and ≤12.5 g/dL * Fluctuation between the two Hb levels closest in time to the baseline visit during the screening period less than 1.5 g/dL * Serum ferritin ≥ 100 ng/mL, or TSAT ≥20% during the screening period * Folate and vitamin B12 ≥ lower limit of normal during the screening period Exclusion Criteria: * Anemia due to a main cause other than CKD: sickle cell disease, myelodysplastic syndrome, bone marrow fibrosis, hematologic malignancy, hemolytic anemia, thalassemia, or pure red cell aplasia * Active bleeding or recent blood loss within 8 weeks prior to the screening period * RBC transfusion within 8 weeks prior to the screening period * Received testosterone enanthate or mepitiostane within 8 weeks prior to the screening period * AST, ALT, or total bilirubin \>2.5 x upper limit of normal during the screening period * Uncontrolled hypertension (diastolic blood pressure \>110 mm Hg or systolic blood press…